Trial · NCT06331000
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate time in range of blood glucose variation >140 mg/dl during 2 weeks in a cohort of adult patients treated for one year with elexacaftor-tezacaftor-ivacaftor | time in range of blood glucose variation >140 mg/dl one year before and one year after the begining of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Evaluate other CGM parameters : time in range of blood glucose >180mg/dl ; >140mg/dl ; <70mg/dl ; 70-180 mg/dl ; 70-140mg/dl | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: HbA1c (mmol/l) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: HbA1c (%) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: C-Peptid (µg/L) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: C-Peptid (nmol/L) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Markers of nutritional status: Evaluation of weight monitoring (kg) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Markers of nutritional status: Body Mass Index (BMI) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Diabetes treatment (assess insulin needs) : mean glucose value per day (mg/dl) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Assessment of respiratory function parameters : number of IV antibiotics | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Number patients with severe hypoglycaemia and serious adverse events | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06331000/registered